Apimeds' subsidiary expanded MindChain to cover climate finance, sports media, and insurance. This creates more possible uses for its digital tools, though the report gives no customer or sales results.
This gives Apimeds more possible uses for its digital tools. The report does not name customers or sales, so it does not show that the wider reach is bringing in money yet.
Follow Apimeds Pharmaceuticals US, Inc. (APUS) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for APUS